Skip to main content

Celcuity Inc.

corporate_fare Company Profile

Celcuity Inc.

CELC·NASDAQ·Life Sciences·CIK 0001603454

Celcuity Inc. is a clinical-stage biotechnology company developing targeted therapies for various solid tumor indications. Its primary therapeutic candidate is gedatolisib, a kinase inhibitor that targets the phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), and mechanistic target of rapamycin (mTOR) pathway. Gedatolisib comprehensively inhibits the PI3K/AKT/mTOR (PAM) pathway by binding to all class I PI3K isoforms and both mTORC1 and mTORC2 complexes. This mechanism of action and its pharmacokinetic properties distinguish it from other approved and investigational therapies that target PI3Kα, AKT, or mTORC1 individually or in combination. The company has completed enrollment for its Phase 3 clinical trial, VIKTORIA-1, which evaluates gedatolisib alongside fulvestrant, with or without palbociclib, in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). Detailed results for cohort 1 (patients with PIK3CA wild-type (WT) tumors) have been reported, and enrollment for cohort 2 (patients with PIK3CA mutant-type (MT) tumors) is complete. Additionally, Celcuity Inc. is conducting the Phase 3 clinical trial, VIKTORIA-2, which is evaluating gedatolisib in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor and fulvestrant as a first-line treatment for patients with endocrine treatment-resistant HR+/HER2- ABC.

Celcuity Inc. (NASDAQ:CELC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for CELC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 13 rated 8 or above. Recent SEC coverage for CELC spans 10-Q, 8-K, SCHEDULE 13D/A, 144.

Recent high-impact activity:

  • FDA Accepts sNDA for REVTORPYK in PIK3CA-Mutant Breast Cancer, PDUFA Set for June 2027
  • Celcuity 10-Q: $642.7M Cash Through 2029, Q3 Loss Widens to $73.3M on Launch Costs
  • Celcuity Q3 Loss Widens to $73.3M as REVTORPYK Launch Begins; $642.7M Cash Funds Through 2029
  • Celcuity Q3 Loss Narrower Than Expected as Launch Spending Runs $77.3M
  • Celcuity Launches REVTORPYK Commercially in the U.S. for HR+/HER2- Advanced Breast Cancer

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$177.04M
Diluted EPS
-$3.79
Op. Cash Flow
-$153.28M
Free Cash Flow
-$153.53M
Operating Income
-$172.19M
Cash & Equivalents
$165.7M
Total Debt
$195.32M
Debt / Equity
1.94×
Shares Outstanding
48.24M sh
Source: 10-K · filed 2026-03-26 · accession 0001493152-26-012801

Short Interest & Short Volume

5.85 days to cover

FINRA reported short interest of 10,303,095 shares in CELC as of the October 30, 2026 settlement, a 0.5% increase from the prior period — about 5.8 days to cover at its recent average daily volume. On November 20, 2026, 55.2% of CELC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)10,303,095 shares as of October 30, 2026
Change vs prior period▲ 0.5%
Days to cover5.85 at avg daily volume of 1,760,779
Daily short volume (FINRA facilities)55.2% of 279,428 shares on November 20, 2026
5-day average short volume44.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for CELC, detected from its recent SEC filings · based on capital-structure filings through 2026-06-05.

1 recent capital raise

$500M Convertible Senior Notes Offering Finalized · Premium Conversion Price Demonstrates Confidence

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$53.35
52-week range · as of 2026-11-05 $53.35 – $151.02
Market cap
$2.62B
Volume
636.5K (0.4× avg)
3-mo avg 1.4M
Live data · 2026-11-22 12:35 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CELC - Latest Insights

CELC
Nov 09, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $66.32
Real-time Price: $53.35 info
Change: -$12.97 (-20%) info
Market Cap: $2.621B info
CELC
Nov 05, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $53.35 info
Change: -$10.69 (-17%) info
Market Cap: $2.621B info
CELC
Nov 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $53.35 info
Change: -$10.69 (-17%) info
Market Cap: $2.621B info
CELC
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $53.35 info
Change: -$10.69 (-17%) info
Market Cap: $2.621B info
CELC
Sep 30, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $79.00
Real-time Price: $53.35 info
Change: -$25.65 (-32%) info
Market Cap: $2.621B info
CELC
Aug 26, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $91.00
Real-time Price: $53.35 info
Change: -$37.65 (-41%) info
Market Cap: $2.621B info
CELC
Aug 13, 2026, 5:15 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $87.01
Real-time Price: $53.35 info
Change: -$33.66 (-39%) info
Market Cap: $2.621B info
CELC
Aug 13, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $88.00
Real-time Price: $53.35 info
Change: -$34.65 (-39%) info
Market Cap: $2.621B info
CELC
Jul 16, 2026, 5:51 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $87.84
Real-time Price: $53.35 info
Change: -$34.49 (-39%) info
Market Cap: $2.621B info
CELC
Jul 15, 2026, 12:06 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $88.89
Real-time Price: $53.35 info
Change: -$35.54 (-40%) info
Market Cap: $2.621B info
CELC
Jul 15, 2026, 6:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $106.00
Real-time Price: $53.35 info
Change: -$52.65 (-50%) info
Market Cap: $2.621B info
CELC
Jul 14, 2026, 9:45 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $111.05
Real-time Price: $53.35 info
Change: -$57.70 (-52%) info
Market Cap: $2.621B info
CELC
Jul 14, 2026, 9:43 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $103.75
Real-time Price: $53.35 info
Change: -$50.40 (-49%) info
Market Cap: $2.621B info
CELC
Jul 14, 2026, 5:39 PM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $106.00
Real-time Price: $53.35 info
Change: -$52.65 (-50%) info
Market Cap: $2.621B info
CELC
Jul 14, 2026, 3:26 PM EDT
Source: Reuters
Importance Score:
10
Price at Filing: $111.66
Real-time Price: $53.35 info
Change: -$58.31 (-52%) info
Market Cap: $2.621B info
CELC
Jun 08, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $87.43
Real-time Price: $53.35 info
Change: -$34.08 (-39%) info
Market Cap: $2.621B info
CELC
Jun 05, 2026, 6:28 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $88.50
Real-time Price: $53.35 info
Change: -$35.15 (-40%) info
Market Cap: $2.621B info
CELC
Jun 04, 2026, 6:17 AM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $87.00
Real-time Price: $53.35 info
Change: -$33.65 (-39%) info
Market Cap: $2.621B info
CELC
Jun 03, 2026, 10:13 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $87.26
Real-time Price: $53.35 info
Change: -$33.91 (-39%) info
Market Cap: $2.621B info
CELC
Jun 03, 2026, 7:28 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $91.50
Real-time Price: $53.35 info
Change: -$38.15 (-42%) info
Market Cap: $2.621B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets